Verition Fund Management
MLYS icon

Verition Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

Verition Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$2.71M – 2359
2026
Q1 		$2.71M Buy
100,000
+50,000
+100% +$1.47M 0.02% 865
2025
Q4 		$1.81M Buy
+50,000
New +$2.01M 0.01% 1697

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Verition Fund Management's MLYS Position: Q2 2026 in Review

Verition Fund Management reduced its Mineralys Therapeutics (MLYS) stake by 63% in Q2 2026, selling an estimated $1.66M and leaving 34,732 shares worth $937K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Verition Fund Management first reported a position in MLYS in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.04M in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Verition Fund Management held 34,732 shares of Mineralys Therapeutics worth $937K as of Q2 2026.
  • Verition Fund Management sold 60,390 Mineralys Therapeutics shares in Q2 2026, an estimated $1.66M.
  • Mineralys Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1444 holding.
  • Verition Fund Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Verition Fund Management's Mineralys Therapeutics position peaked at $3.04M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.